Gedragsmatige activering bij ouderen met een depressie: een alternatieve effectieve behandeling?
- Conditions
- depression in elderlydepressie bij ouderen
- Registration Number
- NL-OMON29645
- Lead Sponsor
- Riagg Maastricht in collaboration with Maastricht University, University of Amsterdam & VU University Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion criteria are 1) primary diagnosis of acute (i.e. started at least 12 months prior to referral) major and minor depression as assessed with the SCID-I; 2) a recurrent depressive episode is allowed; 3) a cut off score of 5/6 on the GDS-15 at screening (12); 4) age range 60-99; 5) can understand and speak the Dutch language; 6) willingness to participate in the study (signed informed consent).
Exclusion criteria are 1) psychotic features, psychotic disorder or bipolar disorder; 2) IQ<80 (clinical impression); 3) acute suicide risk; 4) substance dependence; 5) start of new medication within 3 months before start of the study (medication used for longer periods can be continued; stopping medication during the study is allowed); 6) medical condition that causes depression directly or through medication intake; 7) unstable medical condition; 8) MMSE score <20.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measure will be the change in depression severity between respectively the intervention and exploration phase versus the baseline condition (Δ treatment effect). For the purpose of this study, we have chosen the GDS-15 as primary outcome measure, because Longwell and Truax (2005) warn for weekly administration of the BDI-II leading to decreasing scores merely as a result of the short re-administration period.
- Secondary Outcome Measures
Name Time Method The secondary outcome measures are the BDI-II, the 17-item Hamilton Rating Scale for Depression (HRSD), patient acceptability of intervention (i.e. take up and drop out rates), medication use, patient attrition, happiness (one item question), and quality of life (EuroQol).<br>We will apply the criteria for clinical response and remission as proposed by Dimidjian et al. (2006). They define response as a minimal 50% decline of symptoms compared to baseline, and remission is accomplished if the HRSD scores ≤ 7 and BDI ≤ 10. The SCID-I will be used to evaluate at pre- and post-treatment whether the major/minor depression is still present or in remission.